Seasons change and so do cancer treatments. Lisa had a good run with T-DM1, a total of nine treatments over a six-month period, but the time has come for a change.
T-DM1* worked well for Lisa, however, her CT scans from last Wednesday showed disease progression. With your fingers you can feel that the parotid gland tumors have increased in size and become more defined. The CT scans show that they have increased by about 30% and other lymph node tumors show similar increases. The disease has obviously become resistant to T-DM1, so it’s time for something new and different.
And that something new and different will most likely be GDC-0032; another miracle drug from the wizards at Genetech who brought us T-DM1. GDC-0032 inhibits the PIK3** protein which promotes cancer cell growth. You can think of GDC-0032 as a roadblock on the pathway that signals the cancer cell to grow.
GDC-0032 is so new that it is still in Phase I clinical trials. To receive this treatment, Lisa will enroll in the Phase I trial being conducted at MGH. However, before she can receive her first treatment, she needs to be released from St. Joseph Hospital in Nashua.
Lisa is currently in-patient at St Joseph receiving fluids and medication because she has been unable to keep anything down for the last three days. The exact problem is still unclear, but it is similar to the ileus problem she had back in March. She was looking and feeling much better when I left the hospital this evening and hopefully she will be coming home tomorrow.* Due to the positive T-DM1 trial results the FDA is giving the drug a “priority-review” with a decision due on Feb. 26, 2012. **gobbledygook protein… ok, its really the phosphatidylinositol-3 kinase protein